Search clinical trials for: powered bone marrow aspiration and biopsy device

Total 476906 results

Vidacare Corporation

Completed

A Study Comparing Use of Manual and Power Bone Marrow Aspiration and Biopsy Devices in Children

Bone Marrow Aspiration and Biopsy Specimen Collection

United States
Vidacare Corporation

Completed

Powered Bone Marrow Aspiration and Core Biopsy System Compared to Manual Devices

Bone Marrow Biopsy Procedures

United States, Spain
Vidacare Corporation

Completed

A Study Comparing Powered Ported Bone Marrow Aspiration Procedures to Manual Standard Bone Marrow Aspiration Procedures Using Healthy Volunteers

Healthy

United States
Kerry Rogers

Not yet recruiting

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Hard-to-Treat Multiple Myeloma

Multiple Myeloma
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Not yet recruiting

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Relapsed Myelodysplastic Syndrome

United States
Washington University School of Medicine

Recruiting

Evaluating the Human Immune Response to the JYNNEOS Vaccine

Virus Diseases | Vaccinia

United States
Roswell Park Cancer Institute

Recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recurrent Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia Variant

United States
Narendranath Epperla

Not yet recruiting

Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
Children's Oncology Group

Not yet recruiting

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Juvenile Myelomonocytic Leukemia | Refractory Juvenile Myelomonocytic Leukemia
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Not yet recruiting

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma
Uma Borate

Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
Elvira Umyarova
Sanofi

Recruiting

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma, Nodular

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Passive Music Intervention for the Reduction of Anxiety in Patients Undergoing Bone Marrow Aspiration and/or Biopsy

Hematopoietic and Lymphoid System Neoplasm

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myelodysplastic Syndrome | Clonal Cytopenia of Undetermined Significance

United States
Mayo Clinic

Recruiting

Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Multiple Myeloma

United States
Fred Hutchinson Cancer Center
ImmunoGen, Inc.

Recruiting

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Mixed Phenotype Acute Leukemia

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

AL Amyloidosis
Abdullah Khan

Recruiting

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
Faron Pharmaceuticals Ltd

Not yet recruiting

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Mantle Cell Lymphoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (V-MIND)

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
Mayo Clinic

Recruiting

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
National Cancer Institute (NCI)

Recruiting

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Recurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis

United States, Canada
Sanjay Mohan
National Comprehensive Cancer Network; Taiho Oncology, Inc.

Recruiting

Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant

Recurrent Acute Myeloid Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

Recurrent Severe Aplastic Anemia | Refractory Severe Aplastic Anemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

B Acute Lymphoblastic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Uma Borate

Recruiting

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Clonal Cytopenia of Undetermined Significance

United States
Uskudar University

Not yet recruiting

The Effect of Relaxing Breathing Exercise Applied to Patients Before Bone Marrow Biopsy on Vital Signs, Pain and Anxiety Levels

Bone Marrow Cancer

Turkey
Thomas Jefferson University

Recruiting

Palbociclib or Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Aperture Medical Technology, LLC

Recruiting

A Prospective Study of Conventional Bone Marrow Biopsy Versus Portomar(TM) Biopsy

Hematologic Malignancy

United States
National Cancer Institute (NCI)

Recruiting

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Not yet recruiting

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma

United States, Puerto Rico
Mayo Clinic

Recruiting

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Refractory Chronic Myelomonocytic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Multiple Myeloma | ISS Stage III Plasma Cell Myeloma

United States
University of Washington

Recruiting

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma

United States
University of Washington
Incyte Corporation

Recruiting

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States

Search clinical trials for: powered bone marrow aspiration and biopsy device

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations